Leukogene Therapeutics Inc.
- Biotech or pharma, therapeutic R&D
The mission of Leukogene Therapeutics, Inc (LTI) is to deliver paradigm-shifting therapies for cancer patients. LTI’s proprietary major histocompatibility complex (MHC) class II targeted (M2T™) immunotherapy is like a conductor of the immune system orchestra. It directs many immune components such as B cells, T cells and NK Cells to target tumor cells. By delivering tumor antigens directly to MHC class II proteins, M2T™ elicits a holistic and powerful immune response that selectively kills cancer cells.
With an experienced leadership team in place, strong preclinical efficacy data with our lead asset M2T-CD33 in Acute Myelogenous Leukemia (AML) and M2T-MSLN in pancreatic cancer, and product manufacturing underway, clinical trials are being planned in 12-18 months. LTI is seeking financial and strategic partners to join our pursuit of the next breakthrough in immunotherapy.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}